Seeking Alpha

MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • PSivida Corp. (PSDV) Announces Marketing Authorization For ILUVIEN® In Portugal For The Treatment Of Chronic Diabetic Macular Edema 0 comments
    Jun 6, 2012 2:13 PM | about stocks: PSDV

    pSivida, a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today it has been granted marketing authorization for ILUVIEN® from the National Authority of Medicines and Health Products (Autoridade Nacional do Medicamento e Produtos de Saúde, Infarmed) for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered inadequately responsive to available therapies.

    The company has been granted this marketing authorization after completing the Decentralized Regulatory Procedure (DCP) in the European Union. In the DCP, the Medicines and Healthcare products Regulatory Agency in the United Kingdom, serving as the Reference Member State, gave a positive outcome for ILUVIEN concurrent with the six Concerned Members States of Austria, France, Germany, Italy, Portugal, and Spain.

    "We are pleased our product has received marketing authorization in Portugal. We now have marketing authorization in three of the seven targeted EU countries," said Dr. Paul Ashton, president and chief executive officer of pSivida. "We look forward to ILUVIEN receiving approval in the four remaining CMS countries, France, Germany, Italy and Spain, in the coming months."

    The International Diabetes Federation estimates that over 1,000,000 people live with diabetes in Portugal, as well as more than 55,000 people suffering from vision loss associated with DME, according to Alimera's estimates.

    ILUVIEN is an injectable, sustained-release intravitreal insert that releases sub-microgram levels of fluocinolone acetonide (FAc) for up to 36 months for the treatment of chronic DME. pSivida is developing an insert of the same design for the treatment of uveitis affecting the posterior of the eye.

    For further information, please visit www.psivida.com

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Stocks: PSDV
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.